Kang Jiawen, Xiang Xiaoqing, Chen Xiaoyan, Jiang Jingwen, Zhang Yong, Li Lesai, Tang Jie
Department of Internal Medicine, Medical College of Hunan Normal University, Changsha, Hunan, China.
Department of Pathology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Front Cell Dev Biol. 2023 Jan 12;10:1086835. doi: 10.3389/fcell.2022.1086835. eCollection 2022.
Cervical cancer ranks first in female reproductive tract tumors in terms of morbidity and mortality. Yet the curative effect of patients with persistent, recurrent or metastatic cervical cancer remains unsatisfactory. Although antitumor angiogenic drugs have been recommended as the first-line treatment options for cervical cancer, there are no comprehensive prognostic indicators for cervical cancer based on angiogenic signature genes. In this study, we aimed to develop a model to assess the prognosis of cervical cancer based on angiogenesis-related (AG) signature genes, and to provide some reference for the comprehensive treatment of cervical cancer in the clinical setting. First we screened the AG gene set from GeneCard website, and then performed angiogenesis-related scores (AGS) per cell from single cell sequencing dataset GSE168652, followed by performing weighted gene co-expression network analysis (WGCNA) for cervical cancer patients according to angiogenesis phenotype. Thus, we established a prognostic model based on AGS by taking the intersection of WGCNA angiogenic module gene and differential gene (DEGs) of GSE168652. The GSE44001 was selected as an external validation set, followed by performing ROC curve analysis to assess its accuracy. The results showed that we successfully constructed a prognostic model related to the AG genes. Patients in the high-AGS group in both the train, test and the validation sets had a worse prognosis than those in the low-AGS group, had lower expression of most immune checkpoint-associated genes and lower tumor mutational burden as well. Patients in the low-AGS group were more sensitive to AMG.706, Bosutinib, and Lenalidomide while Imatinib, Pazopanib, and Sorafenib were more recommended to patients in the high-AGS group. Finally, and , which have high hazard ratio and poor prognosis in the model, were highly expressed in cervical cancer cell lines and tissue. Meanwhile, the results showed that promoted the migration of cervical cancer cells and the tubule-forming ability of endothelial cells. In conclusion, our model based on genes with AG features can effectively assess the prognosis of cervical cancer, and can also provide reference for clinicians to choose immune-related treatments.
宫颈癌在女性生殖道肿瘤的发病率和死亡率方面位居首位。然而,持续性、复发性或转移性宫颈癌患者的治疗效果仍然不尽人意。尽管抗肿瘤血管生成药物已被推荐为宫颈癌的一线治疗选择,但基于血管生成特征基因的宫颈癌综合预后指标尚不存在。在本研究中,我们旨在开发一种基于血管生成相关(AG)特征基因的模型来评估宫颈癌的预后,并为临床环境中宫颈癌的综合治疗提供一些参考。首先,我们从GeneCard网站筛选AG基因集,然后从单细胞测序数据集GSE168652计算每个细胞的血管生成相关评分(AGS),接着根据血管生成表型对宫颈癌患者进行加权基因共表达网络分析(WGCNA)。因此,我们通过取WGCNA血管生成模块基因与GSE168652的差异基因(DEGs)的交集,建立了基于AGS的预后模型。选择GSE44001作为外部验证集,随后进行ROC曲线分析以评估其准确性。结果表明,我们成功构建了一个与AG基因相关的预后模型。在训练集、测试集和验证集中,高AGS组患者的预后均比低AGS组差,大多数免疫检查点相关基因的表达较低,肿瘤突变负担也较低。低AGS组患者对AMG.706、博舒替尼和来那度胺更敏感,而高AGS组患者更推荐使用伊马替尼、帕唑帕尼和索拉非尼。最后,在模型中具有高风险比和不良预后的 和 在宫颈癌细胞系和组织中高表达。同时,结果表明 促进了宫颈癌细胞的迁移和内皮细胞的管腔形成能力。总之,我们基于具有AG特征的基因的模型可以有效地评估宫颈癌的预后,也可以为临床医生选择免疫相关治疗提供参考。